Sanofi News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

18.10.23	Sanofi: PROTECT Trial Data Showcase Potential Of TZIELD - Quick Facts (RTTNews)
18.10.23	Press Release: TZIELD® Phase 3 data presented at ISPAD shows potential to slow the progression of Stage 3 type 1 diabetes in newly diagnosed children and adolescents; full data simultaneously publishe (GlobeNewswire)
17.10.23	Sanofi: Information concerning the total number of voting rights and shares - September 2023 (GlobeNewswire)
13.10.23	Press Release: Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis (GlobeNewswire)
04.10.23	Teva To Get Up To $1.5 Bln In Deal With Sanofi To Co-develop Inflammatory Bowel Disease Treatment (RTTNews)
04.10.23	Press Release: Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment (GlobeNewswire)
04.10.23	Press Release: Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment (GlobeNewswire)
03.10.23	Press Release: Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli (GlobeNewswire)
26.09.23	Sanofi: SBLA For Dupixent Gets Priority Review From FDA (RTTNews)
26.09.23	Press Release: Dupixent® (dupilumab) sBLA for treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority Review (GlobeNewswire)
25.09.23	Press Release: Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia A (GlobeNewswire)
22.09.23	Sanofi: Foreign Currency To Negatively Impact Q3 Sales, Business EPS - Quick Facts (RTTNews)
22.09.23	Press Release: Availability of the Q3 2023 Memorandum for modelling purposes (GlobeNewswire)
19.09.23	Press Release: Sanofi supporting vulnerable communities as part of commitment to social impact and fight against climate change (GlobeNewswire)
14.09.23	First Wave BioPharma To Receive Global License For Capeserod From Sanofi; Stock Surges (RTTNews)
11.09.23	Sanofi: Information concerning the total number of voting rights and shares - August 2023 (GlobeNewswire)
31.08.23	Press Release: Sanofi announces changes to its Executive Committee (GlobeNewswire)
15.08.23	Sanofi: Information concerning the total number of voting rights and shares - July 2023 (GlobeNewswire)
03.08.23	Press Release: U.S. CDC Advisory Committee unanimously recommends routine use of Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease (GlobeNewswire)
28.07.23	Press release: Online availability of Sanofi’s half-year financial report for 2023 (GlobeNewswire)
28.07.23	Sanofi Q2 Profit Rises, Sales Up 3.3% At CER; Raises 2023 Business EPS Guidance (RTTNews)
28.07.23	Press Release: Sanofi to acquire Qunol®, a fast-growing U.S. brand in the healthy aging segment (GlobeNewswire)
28.07.23	Press Release: Solid Q2 performance and strong pipeline momentum, Full-year 2023 business EPS guidance raised (GlobeNewswire)
18.07.23	Sanofi: Information concerning the total number of voting rights and shares – June 2023 (GlobeNewswire)
18.07.23	FDA Approves AstraZeneca And Sanofi's Beyfortus To Protect Infants Against RSV Disease (RTTNews)
17.07.23	Press Release: FDA approves Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease (GlobeNewswire)
30.06.23	SK Reports Positive Results From Phase II Study Of 21-Valent Pneumococcal Conjugate Vaccine (RTTNews)
29.06.23	Press Release: Vaccines R&D pipeline raises the bar in RSV, influenza, meningitis, and pneumococcal disease (GlobeNewswire)
27.06.23	Sanofi Reports Positive Topline Phase 2b Data In Atopic Dermatitis With Amlitelimab (RTTNews)
27.06.23	Press Release: Positive topline Phase 2b data in atopic dermatitis support amlitelimab as a potential first and best-in-class novel investigational anti-OX40-ligand monoclonal antibody (GlobeNewswire)
25.06.23	Press Release: ALTUVIIIO late-breaking data at ISTH demonstrates highly effective bleed protection in children with severe hemophilia A with once-weekly dosing (GlobeNewswire)
22.06.23	Press Release: Availability of the Q2 2023 Memorandum for modelling purposes (GlobeNewswire)
20.06.23	Sanofi: Information concerning the total number of voting rights and shares - May 2023 (GlobeNewswire)
20.06.23	Sanofi Prevails In Zantac Arbitration In International Chamber Of Commerce Dispute - Quick Facts (RTTNews)
20.06.23	Press Release: Sanofi prevails in Zantac arbitration initiated by Boehringer Ingelheim (GlobeNewswire)
13.06.23	Press Release: Sanofi “all in” on artificial intelligence and data science to speed breakthroughs for patients (GlobeNewswire)
08.06.23	Press Release: FDA Advisory Committee unanimously recommends nirsevimab as first immunization against RSV disease for all infants (GlobeNewswire)
01.06.23	Press Release: Sanofi launches 2023 global Employee Stock Purchase Plan (GlobeNewswire)
31.05.23	Sanofi: Frexalimab Phase 2 Trial Meets Primary Goal In Relapsing Multiple Sclerosis (RTTNews)
31.05.23	Press Release: Positive Phase 2 data of novel investigational anti-CD40L antibody frexalimab show significantly reduced disease activity in relapsing multiple sclerosis (GlobeNewswire)
25.05.23	Press Release: Annual General Meeting of May 25, 2023 – Frédéric Oudéa new Chairman of the Board of Directors (GlobeNewswire)
22.05.23	Sanofi:Dupixent Phase 3 COPD Results Presented At ATS & Published In New England Journal Of Medicine (RTTNews)
21.05.23	Press Release: Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine (GlobeNewswire)
19.05.23	U.S. Supreme Court Rules Against Amgen In Cholesterol Drug Patent Dispute With Sanofi (RTTNews)
17.05.23	Sanofi: Information concerning the total number of voting rights and shares – April 2023 (GlobeNewswire)
12.05.23	Sanofi: Nirsevimab Delivers 83% Reduction In RSV Infant Hospitalizations In Phase 3b Trial (RTTNews)
12.05.23	Press Release: Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting (GlobeNewswire)
04.05.23	Sanofi: COMBINED GENERAL MEETING OF MAY 25, 2023 - AVAILABILITY OF PREPARATORY DOCUMENTS (GlobeNewswire)
27.04.23	Press Release: Sanofi completes acquisition of Provention Bio, Inc. (GlobeNewswire)
27.04.23	Press Release: Strong Q1 growth driven by Specialty Care, Vaccines and CHC (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

22.11.24		Dow Jones aktuell: Dow Jones zum Ende des Freitagshandels in der Gewinnzone
22.11.24		S&P 500-Handel aktuell: S&P 500 liegt letztendlich im Plus
22.11.24		Freundlicher Handel: NASDAQ 100 verbucht zum Ende des Freitagshandels Zuschläge
22.11.24		Gute Stimmung in New York: nachmittags Pluszeichen im S&P 500
22.11.24		Gewinne in New York: NASDAQ 100 präsentiert sich fester
22.11.24		Freundlicher Handel in New York: Dow Jones präsentiert sich am Freitagnachmittag fester
22.11.24		Börse New York in Grün: Dow Jones bewegt sich am Mittag im Plus

22.11.24

Dow Jones aktuell: Dow Jones zum Ende des Freitagshandels in der Gewinnzone

22.11.24

S&P 500-Handel aktuell: S&P 500 liegt letztendlich im Plus

22.11.24

Freundlicher Handel: NASDAQ 100 verbucht zum Ende des Freitagshandels Zuschläge

22.11.24

Gute Stimmung in New York: nachmittags Pluszeichen im S&P 500

22.11.24

Gewinne in New York: NASDAQ 100 präsentiert sich fester

22.11.24

Freundlicher Handel in New York: Dow Jones präsentiert sich am Freitagnachmittag fester